Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Rodriguez

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
New Biotechnology|June 13, 2024
Autotrophic adaptive laboratory evolution of the acetogen Clostridium autoethanogenum delivers the gas-fermenting strain LAbrini with superior growth, products, and robustnessHenri Ingelman, James K Heffernan, Audrey Harris, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma, Joshua Richter, Sundar Jagannath, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
New Biotechnology|June 13, 2024
Autotrophic adaptive laboratory evolution of the acetogen Clostridium autoethanogenum delivers the gas-fermenting strain LAbrini with superior growth, products, and robustnessHenri Ingelman, James K Heffernan, Audrey Harris, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma, Joshua Richter, Sundar Jagannath, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Pageof 5